Why the study?
Thrombocytopenia is a rare complication of novel oral anticoagulants such as rivaroxaban.
Does rivaroxaban cause thrombocytopenia in patients with DVT?
Does rivaroxaban cause thrombocytopenia in patients with DVT?
Rivaroxaban, a novel oral anticoagulant, can rarely induce thrombocytopenia in patients being treated for deep vein thrombosis.
Answers are grounded in this paper and cite their sources.
Possible rivaroxaban-induced thrombocytopenia warrants platelet monitoring in DVT; case report leaves open incidence and causality.
Novel oral anticoagulants (NOACs) are used as alternative to intravenous anticoagulants. It includes apixaban, dabigatran, rivaroxaban and edoxaban.1 Some of the complications induced by these drugs are gastrointestinal haemorrhage, cerebral haemorrhage and rarely thrombocytopenia. We present a rare case report of a selective factor Xa inhibitor rivaroxaban, which induced thrombocytopenia in a case of deep vein thrombosis (DVT) of right lower limb. Drugs commonly used to prevent embolization of systemic circulation are warfarin and novel oral anticoagulants, such as rivaroxaban and dabigatran.
No takes yet. Share an insight, caveat, or question.
Pawar et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: